Ignite Creation Date:
2024-05-06 @ 10:57 AM
Last Modification Date:
2024-10-26 @ 12:38 PM
Study NCT ID:
NCT03393858
Status:
TERMINATED
Last Update Posted:
2024-02-07
First Post:
2018-01-03
Brief Title:
Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma
Sponsor:
Capital Medical University
Organization:
Capital Medical University
Study Overview
Official Title:
A Prospective Study of Combination of Anti-PD-1 Plus Autologous DC-CIK Cell Immunotherapy and Hyperthermia for Patients With Advanced Malignant Mesothelioma
Status:
TERMINATED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The number of enrolled cases is insufficient
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the clinical efficacy and toxicity of anti-PD-1 monoclonal antibody plus autologous dendritic cells-cytokine induced killer cell DC-CIK immunotherapy combined with hyperthermia in advanced malignant mesothelioma patientsFurthermoreto characterize response to therapythe investigators intent to explore the predictive biomarker for this regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None